The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) translational study.
 
David Silva Moura
Research Funding - Eisai (Inst); Immix Biopharma (Inst); Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Celgene; Eisai; Pfizer; PharmaMar
 
Nadia Hindi
Honoraria - Lilly; PharmaMar
Research Funding - Amgen (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Maria Lopez-Alvarez
Research Funding - PharmaMar (Inst)
 
Paloma Sanchez-Bustos
Research Funding - PharmaMar (Inst)
 
Irene Carrasco-Garcia
No Relationships to Disclose
 
Paloma Santos-Fernandez
No Relationships to Disclose
 
Paula Martinez-Delgado
Travel, Accommodations, Expenses - Bayer; Roche
 
Serena Lacerenza
Research Funding - PharmaMar (Inst)
 
Elena Blanco-Alcaina
No Relationships to Disclose
 
Jose Lucinio Mondaza-Hernandez
No Relationships to Disclose
 
Antonio Gutierrez
No Relationships to Disclose
 
Rosa Maria Alvarez
Honoraria - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; PharmaMar
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; PharmaMar
Research Funding - Abbvie; AstraZeneca; Bluprint Oncology Concepts; Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merrimack; MSD Oncology (Inst); Novartis (Inst); PharmaMar; Roche/Genentech; Takeda (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - PharmaMar; Roche
 
Magda Cordeiro
No Relationships to Disclose
 
Luis Miguel De Sande González
No Relationships to Disclose
 
Gloria Marquina
Honoraria - AstraZeneca Spain; Eisai; Eisai; Grunenthal; Grunenthal; Lilly; MSD Oncology; PharmaMar; Roche; Roche; Tesaro
Consulting or Advisory Role - Clovis Oncology; PharmaMar; PharmaMar; Tesaro
Travel, Accommodations, Expenses - Acraf; Eisai; Eisai; Lilly; Merck; MSD; Pfizer; Pfizer; PharmaMar; PharmaMar; PharmaMar; PharmaMar; PharmaMar; Roche; Roche; Roche; Roche; Roche; Roche; Roche; Tesaro; Tesaro
Other Relationship - GlaxoSmithKline; Tesaro; Tesaro
 
Juana Maria Cano
No Relationships to Disclose
 
Josefina Cruz Jurado
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Lilly; Novartis; Pfizer; PharmaMar; Roche
Speakers' Bureau - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; PharmaMar; Roche
Travel, Accommodations, Expenses - Novartis; PharmaMar
 
Claudia Maria Valverde Morales
Consulting or Advisory Role - Bayer; Eisai; Lilly; Novartis; Pfizer; PharmaMar
Research Funding - Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Novartis; Pfizer; PharmaMar
 
Javier Martinez-Trufero
Consulting or Advisory Role - PharmaMar
Research Funding - Blueprint Medicines (Inst); Lilly (Inst); PharmaMar (Inst)
Expert Testimony - PharmaMar
Travel, Accommodations, Expenses - Amgen; Merck; PharmaMar; PharmaMar
 
Javier Martin Broto
Honoraria - Bayer; Eisai; Lilly; PharmaMar
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar